A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials
Immunotherapy · 2024
DOI: 10.2217/imt-2023-0184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy, 2024. Verfasst von Tulay Kus und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Department of Medical Oncology, Gaziantep University, Gaziantep, 27310, Turkey. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
A consensus guideline, iRECIST, was developed by the Response Evaluation Criteria in Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in cancer immunotherapy trials. iRECIST was designed to separate pseudoprogression from real progression. However, this is not the only ambiguous situation. In clinical immunotherapy trials, stable disease may reflect three tumor responses, including real stable disease, progressive disease and responsive disease. The prediction of a "true complete/partial response" is also important. Much data has accumulated showing that ctDNA can guide decisions at this point; thus, integrating ctDNA into the RECIST 1.1 criteria may help to distinguish a true tumor response type earlier in patients treated with immunotherapy; however, prospectively designed validation studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Department of Medical Oncology, Gaziantep University, Gaziantep, 27310, Turkey.
- Department of Medical Oncology, Istinye University Topkapı Health Sciences Campus, Istanbul, 34295, Turkey.
ORCID-Profile: Tulay Kus
Zitieren
APA
Kus, T., & Cicin, I. (2024). A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials. Immunotherapy. https://doi.org/10.2217/imt-2023-0184
Vancouver
Kus T, Cicin I. A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials. Immunotherapy. 2024. doi:10.2217/imt-2023-0184
BibTeX
@article{Kus2024,
author = {Kus, Tulay and Cicin, Irfan},
title = {A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials},
journal = {Immunotherapy},
year = {2024},
doi = {10.2217/imt-2023-0184}
}
EUVIMED